During the corresponding time, Mirum Pharmaceuticals Inc recorded a revenue increase by 37.92 % year on year, sequentially revenue grew by 10.23 %. While revenue at the Mirum Pharmaceuticals Inc 's corporate clients
Mirum Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company markets and commercializes Livmarli in the U.S., Canada, and certain European countries through its specialized commercial team and holds license and distribution agreements with several rare disease companies for additional countries. It acquired assets related to chenodiol and Cholbam (Bile Acid Medicines) from Travere Therapeutics, Inc., which are FDA-approved treatments for bile acid synthesis disorders and cerebrotendinous xanthomatosis (CTX). The company markets Cholbam and Ctexli (chenodiol) in the U.S. and maintains license and distribution agreements with rare disease companies for other countries. It is developing volixibat for cholestatic liver diseases, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), with FDA breakthrough therapy and orphan drug designations. Additionally, the company acquired Bluejay Therapeutics, Inc. and is advancing brelovitug for chronic hepatitis D virus infection, which has FDA Breakthrough Therapy designation and EMA recognition.
In an exciting development for patients suffering from progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals, Inc. announced that LIVMARLI (Maralixibat), an oral solution, has received market approval from the European Commission. This authorization comes after a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP), which recognized LIVMARLI s significant clinical benefits for PFIC patients aged three months and above. Furthermore, Mirum Pharmaceuticals Inc. has experienced a notable surge in revenue over the corresponding period, reflecting the positive growth and market potential of their pharmaceutical offerings.LIVMARLI Approval for PFIC Treatment:M...
Mirum Pharmaceuticals Achieves Milestone with Significant Revenue Growth Foster City, California Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has announced that the European Commission has granted marketing authorization for LIVMARLI (Maralixibat) oral solution. This approval marks a significant development for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged three months and older. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), which concluded that LIVMARLI demonstrates substantial clinical benefit in treating PFIC.PFIC is a rare and life-threatening liver disorder that impairs the flow of bile, leading to severe li...
Mirum Pharmaceuticals: Long-Term LIVMARLI Data Highlights Positive Outcomes at EASL Congress in Milan Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) recently unveiled significant findings at the Annual Congress of the European Association for the Study of the Liver (EASL) in Milan, which took place from June 5 to June 8, 2024. The new data focused on the long-term efficacy of LIVMARLI (maralixibat), an oral solution, in treating patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). These findings reveal promising therapeutic benefits for patients, furthering LIVMARLI’s reputation as a critical advancement in liver disease treatment. Long-Term Data on LIVMARLIThe exte...
Mirum Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company markets and commercializes Livmarli in the U.S., Canada, and certain European countries through its specialized commercial team and holds license and distribution agreements with several rare disease companies for additional countries. It acquired assets related to chenodiol and Cholbam (Bile Acid Medicines) from Travere Therapeutics, Inc., which are FDA-approved treatments for bile acid synthesis disorders and cerebrotendinous xanthomatosis (CTX). The company markets Cholbam and Ctexli (chenodiol) in the U.S. and maintains license and distribution agreements with rare disease companies for other countries. It is developing volixibat for cholestatic liver diseases, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), with FDA breakthrough therapy and orphan drug designations. Additionally, the company acquired Bluejay Therapeutics, Inc. and is advancing brelovitug for chronic hepatitis D virus infection, which has FDA Breakthrough Therapy designation and EMA recognition.
Sources:
Mirum Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mirum Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Mirum Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
137.61 %